SG11201704843QA - Parg inhibitory compounds - Google Patents
Parg inhibitory compoundsInfo
- Publication number
- SG11201704843QA SG11201704843QA SG11201704843QA SG11201704843QA SG11201704843QA SG 11201704843Q A SG11201704843Q A SG 11201704843QA SG 11201704843Q A SG11201704843Q A SG 11201704843QA SG 11201704843Q A SG11201704843Q A SG 11201704843QA SG 11201704843Q A SG11201704843Q A SG 11201704843QA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitory compounds
- parg inhibitory
- parg
- compounds
- inhibitory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422771 | 2014-12-19 | ||
| PCT/GB2015/054064 WO2016097749A1 (en) | 2014-12-19 | 2015-12-17 | Parg inhibitory compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704843QA true SG11201704843QA (en) | 2017-07-28 |
Family
ID=54937310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704843QA SG11201704843QA (en) | 2014-12-19 | 2015-12-17 | Parg inhibitory compounds |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10508086B2 (ru) |
| EP (2) | EP3907224A1 (ru) |
| JP (1) | JP6673920B2 (ru) |
| KR (1) | KR102682782B1 (ru) |
| CN (2) | CN107295799B (ru) |
| AU (1) | AU2015365602B2 (ru) |
| BR (1) | BR112017012707B1 (ru) |
| CA (1) | CA2969298C (ru) |
| ES (1) | ES2886471T3 (ru) |
| HK (1) | HK1245253A1 (ru) |
| IL (1) | IL252745B (ru) |
| MA (1) | MA41179A (ru) |
| MX (1) | MX2017007976A (ru) |
| RU (1) | RU2017125520A (ru) |
| SG (1) | SG11201704843QA (ru) |
| WO (1) | WO2016097749A1 (ru) |
| ZA (1) | ZA201704383B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| WO2020205646A2 (en) * | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Small molecule parg inhibitors and methods of use thereof |
| JP2022548690A (ja) * | 2019-09-20 | 2022-11-21 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
| AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| WO2023154913A1 (en) * | 2022-02-14 | 2023-08-17 | Arase Therapeutics Inc. | Inhibitors of parg |
| CN116693519A (zh) * | 2022-03-04 | 2023-09-05 | 上海璎黎药业有限公司 | 一种含五元杂芳环结构化合物、其药物组合物及应用 |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| AR128846A1 (es) * | 2022-03-23 | 2024-06-19 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg |
| CN114685283B (zh) * | 2022-04-06 | 2024-02-27 | 南京艾康生物科技有限公司 | 一种1-(氟甲基)环丙胺盐酸盐的制备方法 |
| WO2023205914A1 (en) * | 2022-04-28 | 2023-11-02 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| CN117157299B (zh) * | 2022-04-28 | 2024-05-28 | 北京丹擎医药科技有限公司 | 三环杂环衍生物及其组合物和应用 |
| US11939335B2 (en) | 2022-05-17 | 2024-03-26 | 858 Therapeutics, Inc. | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG |
| WO2024017306A1 (zh) * | 2022-07-19 | 2024-01-25 | 苏州信诺维医药科技股份有限公司 | 含硫杂芳环化合物、其药物组合物及其用途 |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| WO2024074497A1 (en) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Parg inhibitory compound |
| KR20240051861A (ko) * | 2022-10-13 | 2024-04-22 | 한미약품 주식회사 | Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물 |
| WO2024120519A1 (zh) * | 2022-12-09 | 2024-06-13 | 捷思英达控股有限公司 | Tead抑制剂、其制备方法和在医学上的应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1157858A (en) | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Quinazoline derivatives |
| DE4407047A1 (de) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
| WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CZ303692B6 (cs) | 1999-02-10 | 2013-03-13 | Astrazeneca Ab | Chinazolinové deriváty jako inhibitory angiogeneze |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (ru) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хиназолиновые производные для лечения опухолей и фармацевтическая композиция |
| RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
| WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| EP2206715A1 (en) | 2004-02-24 | 2010-07-14 | Japan Tobacco, Inc. | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| EP1735306A2 (en) | 2004-03-25 | 2006-12-27 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| WO2007014226A2 (en) * | 2005-07-26 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Compounds for the treatment of neurodegeneration and stroke |
| NZ568910A (en) | 2006-01-24 | 2011-04-29 | Lilly Co Eli | Indole sulfonamide modulators of progesterone receptors |
| JP2009530342A (ja) | 2006-03-20 | 2009-08-27 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法 |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| KR20100122512A (ko) * | 2008-07-17 | 2010-11-22 | 아사히 가세이 파마 가부시키가이샤 | 질소 함유 이환성 복소환 화합물 |
| CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
| SG182351A1 (en) | 2010-01-13 | 2012-08-30 | Glaxosmithkline Llc | Compounds and methods |
| JP5864546B2 (ja) * | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| EP2566477B1 (en) | 2010-05-07 | 2015-09-02 | GlaxoSmithKline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| WO2012080284A2 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| EP2471363A1 (de) | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen |
| WO2012160464A1 (en) | 2011-05-26 | 2012-11-29 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| SG11201504740UA (en) | 2012-12-27 | 2015-07-30 | Univ Drexel | Novel antiviral agents against hbv infection |
| CN105980365B (zh) | 2014-02-11 | 2019-06-21 | 拜耳医药股份公司 | 作为mIDH1抑制剂的苯并咪唑-2-胺 |
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
-
2015
- 2015-12-16 MA MA041179A patent/MA41179A/fr unknown
- 2015-12-17 RU RU2017125520A patent/RU2017125520A/ru not_active Application Discontinuation
- 2015-12-17 JP JP2017532912A patent/JP6673920B2/ja active Active
- 2015-12-17 CA CA2969298A patent/CA2969298C/en active Active
- 2015-12-17 EP EP21179871.5A patent/EP3907224A1/en active Pending
- 2015-12-17 WO PCT/GB2015/054064 patent/WO2016097749A1/en active Application Filing
- 2015-12-17 US US15/533,819 patent/US10508086B2/en active Active
- 2015-12-17 ES ES15813554T patent/ES2886471T3/es active Active
- 2015-12-17 CN CN201580075709.0A patent/CN107295799B/zh active Active
- 2015-12-17 BR BR112017012707-5A patent/BR112017012707B1/pt active IP Right Grant
- 2015-12-17 EP EP15813554.1A patent/EP3233845B1/en active Active
- 2015-12-17 KR KR1020177019869A patent/KR102682782B1/ko active IP Right Grant
- 2015-12-17 CN CN202110213641.5A patent/CN112979631A/zh active Pending
- 2015-12-17 MX MX2017007976A patent/MX2017007976A/es unknown
- 2015-12-17 AU AU2015365602A patent/AU2015365602B2/en active Active
- 2015-12-17 SG SG11201704843QA patent/SG11201704843QA/en unknown
-
2017
- 2017-06-07 IL IL252745A patent/IL252745B/en active IP Right Grant
- 2017-06-28 ZA ZA2017/04383A patent/ZA201704383B/en unknown
-
2018
- 2018-04-04 HK HK18104517.6A patent/HK1245253A1/zh unknown
-
2019
- 2019-10-24 US US16/662,997 patent/US10995073B2/en active Active
-
2021
- 2021-03-17 US US17/204,206 patent/US20210380539A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL252745B (en) | 2020-03-31 |
| RU2017125520A3 (ru) | 2019-06-06 |
| WO2016097749A1 (en) | 2016-06-23 |
| CN112979631A (zh) | 2021-06-18 |
| ES2886471T3 (es) | 2021-12-20 |
| US20200165208A1 (en) | 2020-05-28 |
| MX2017007976A (es) | 2018-03-26 |
| KR102682782B1 (ko) | 2024-07-12 |
| CN107295799A (zh) | 2017-10-24 |
| IL252745A0 (en) | 2017-08-31 |
| AU2015365602B2 (en) | 2020-02-27 |
| US10508086B2 (en) | 2019-12-17 |
| EP3233845B1 (en) | 2021-07-21 |
| ZA201704383B (en) | 2022-03-30 |
| CA2969298A1 (en) | 2016-06-23 |
| JP2017538750A (ja) | 2017-12-28 |
| KR20170095370A (ko) | 2017-08-22 |
| US10995073B2 (en) | 2021-05-04 |
| JP6673920B2 (ja) | 2020-03-25 |
| AU2015365602A1 (en) | 2017-06-29 |
| CA2969298C (en) | 2023-10-17 |
| BR112017012707B1 (pt) | 2023-10-24 |
| CN107295799B (zh) | 2021-03-16 |
| RU2017125520A (ru) | 2019-01-21 |
| US20180194738A1 (en) | 2018-07-12 |
| EP3907224A1 (en) | 2021-11-10 |
| NZ732394A (en) | 2024-01-26 |
| HK1245253A1 (zh) | 2018-08-24 |
| BR112017012707A2 (pt) | 2018-01-02 |
| MA41179A (fr) | 2017-10-24 |
| US20210380539A1 (en) | 2021-12-09 |
| EP3233845A1 (en) | 2017-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| HK1245253A1 (zh) | Parg抑制化合物 | |
| AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
| GB201415573D0 (en) | Compounds | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| GB201411418D0 (en) | Compounds | |
| GB201418300D0 (en) | Compounds | |
| GB201410430D0 (en) | Compounds | |
| GB201402431D0 (en) | Compounds | |
| GB201417369D0 (en) | Compounds | |
| GB201416186D0 (en) | Compounds | |
| GB201417561D0 (en) | Compounds | |
| GB201404987D0 (en) | Compounds | |
| GB201406591D0 (en) | Compounds | |
| GB201419228D0 (en) | Compounds | |
| GB201406956D0 (en) | Compounds | |
| AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201419264D0 (en) | Compounds | |
| GB201412660D0 (en) | Compounds | |
| GB201417168D0 (en) | Compounds | |
| GB201419015D0 (en) | Compounds | |
| GB201407695D0 (en) | Compounds | |
| GB201405361D0 (en) | Compounds | |
| GB201607978D0 (en) | Inhibitory compounds | |
| GB201418154D0 (en) | Inhibitors |